Drug Combination Details
| General Information of the Combination (ID: C49336) | |||||
|---|---|---|---|---|---|
| Name | Bismuth (III) NP Info | + | 6-mercaptopurine Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Decrease | Cell proliferation capacity | ||||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The combination of Bi(III) with 6-MP endowed the newly developed amorphous [Bi(MP)3(NO3)2]NO3 with excellent anticancer activity against lung cancer cells and the solubility and bioavailability of the obtained [Bi(MP)3(NO3)2]NO3 were dramatically improved, compared with that of 6-MP. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Improvement in the Anticancer Activity of 6-Mercaptopurine via Combination with Bismuth(III). Chem Pharm Bull (Tokyo). 2016;64(11):1539-1545. | |||
